AbbVie Inc., a global biopharmaceutical leader headquartered in the United States, was established in 2013 as a spin-off from Abbott Laboratories. With a strong presence in North America, Europe, and Asia, AbbVie focuses on developing advanced therapies in immunology, oncology, neuroscience, and virology. The company is renowned for its flagship product, Humira, which has transformed the treatment landscape for autoimmune diseases. AbbVie’s commitment to innovation is evident in its robust pipeline of biologics and small molecules, addressing unmet medical needs. Recognised for its significant contributions to healthcare, AbbVie consistently ranks among the top biopharmaceutical companies worldwide, driven by a mission to improve patient outcomes through science and research.
How does Abbvie's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Abbvie's score of 62 is higher than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2024, AbbVie reported total carbon emissions of approximately 300,072,000 kg CO2e for Scope 1 and 122,287,000 kg CO2e for Scope 2. This marks a reduction from 2023, where emissions were about 328,259,000 kg CO2e for Scope 1 and 131,232,000 kg CO2e for Scope 2. The company has set ambitious targets to reduce its absolute Scope 1 and 2 greenhouse gas emissions by 42% by 2030, using 2021 as the baseline year. This commitment is part of AbbVie's broader strategy to enhance sustainability and combat climate change. AbbVie also aims to achieve a 25% reduction in absolute carbon emissions by 2025, compared to a 2015 baseline. Furthermore, the company has committed to sourcing 100% renewable electricity by 2030, up from 29.5% in 2021. By 2027, AbbVie plans for 79.1% of its suppliers, based on emissions from purchased goods and services, to have science-based targets. In terms of long-term goals, AbbVie is targeting a 50% reduction in absolute carbon emissions (Scope 1 and 2) by 2035, relative to the 2015 baseline. The company has also pledged to achieve net-zero emissions by 2050. All emissions data and reduction targets are sourced from AbbVie Inc., reflecting its commitment to sustainability within the pharmaceutical sector.
Access structured emissions data, company-specific emission factors, and source documents
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|
Scope 1 | 402,448,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 2 | 418,473,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Scope 3 | - | - | - | - | - | - | - | - | - | - |
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Abbvie is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.